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Background: Shortly after allergen exposure, the number of bone marrow (BM) and circu-
lating CD34+ progenitors increases. We aim to analyze the possible mechanism whereby
the allergic reaction stimulates BM to release these effector cells in increased numbers.
We hypothesize that mast cells (MCs) may play a predominant role in this process.
Objective:To examine the effect of IgE-activated MCs on BM mesenchymal stromal cells
which regulate proliferation and differentiation of CD34+ progenitors.
Methods: Primary MCs were derived from CD34+ precursors and activated with IgE/anti-
IgE. BM mesenchymal stromal cells were co-cultured with CD34+ progenitor cells and
stimulated with IL-1/TNF or IgE/anti-IgE-activated MCs in Transwell system.
Results: BM mesenchymal stromal cells produce low level of thymic stromal lymphopoi-
etin (TSLP) under steady state conditions, which is markedly increased by stimulation with
proinflammatory cytokines IL-1 andTNF or IgE-activated MCs.The latter also triggers bone
marrow-derived mesenchymal stromal cells production of G-CSF, and GM-CSF while inhibit-
ing SDF-1. MC-activated mesenchymal stromal cells stimulate CD34+ cells to proliferate
and to regulate their expression of early allergy-associated genes.
Conclusion and Clinical Relevance: This in vitro study indicates that IgE-activated MCs
trigger BM mesenchymal stromal cells to release TSLP and hematopoietic growth factors
and to regulate the proliferation and lineage commitment of CD34+ precursor cells. The
data predict that the effective inhibition of MCs should impair mobilization and accumulation
of allergic effector cells and thereby reduce the severity of allergic diseases.
Keywords: mast cells, bone marrow mesenchymal stromal cells,TSLP, circulating CD34+ progenitor cells, asthma,
allergic inflammation,Th2 response
INTRODUCTION
Although the initial manifestations of a mucosal allergic reac-
tion are localized, recent studies underline a systemic compo-
nent of allergic diseases and suggest an important role of the
bone marrow (BM) in the control of allergic response. Indeed,
shortly after allergen exposure BM releases increased numbers
of CD34+ hematopoietic precursors and differentiated proin-
flammatory myeloid cells (1–3). CD34+ precursors are rapidly
recruited to the site of allergen deposition where they display a
dual function as both precursors differentiating into eosinophils,
basophils, and mast cells (MCs), and proinflammatory effectors
Abbreviations: BM, bone marrow; BM-MSCs, bone marrow-derived mesenchymal
stromal cells; DCs, dendritic cells; MCs, mast cells; SDF-1, stromal derived factor 1;
TSLP, thymic stromal lymphopoietin.
releasing high levels of Th2 cytokines/chemokines (4). However,
the specific mechanisms underlying airway allergen exposure and
communication with the BM leading to augmented numbers of
progenitor cells and their increased release remain to be elucidated.
Bone marrow-derived mesenchymal stromal cells (BM-MSCs)
are multipotent progenitor cells with immunomodulatory prop-
erties [reviewed in Ref. (5)]. Recent studies suggest that BM-
MSCs themselves are critical for forming a niche that maintains
hematopoietic stem cells (HSCs) and responsible for the pro-
duction and deposition of the extracellular matrix, the produc-
tion and concentration of cytokines, and growth factors (6–8).
MCs originate from HSCs, which circulate as CD34+ precur-
sors until they migrate into tissues where they mature to effector
cells. Both CD34+ precursors and MCs actively participate in the
induction of allergic inflammation by producing high levels of
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Th2 proinflammatory cytokines in response to inflammatory and
epithelial cell-derived cytokines, including thymic stromal lym-
phopoietin (TSLP) (4, 9). Since MCs are sentinels of the innate
immune system and respond very rapidly (within minutes) by
releasing different mediators, they are the best candidates for the
early signals generated during allergic response that may impact
hematopoietic progenitor cell differentiation/mobilization. Here
we tested in an in vitro model the hypothesis that signals pro-
duced by inflamed tissues and local microenvironment at the site
of allergic inflammation may have a significant role in determin-
ing the communication with the BM stroma and MCs may play
important role in this cross-talk.
MATERIALS AND METHODS
CD34+ AND PRIMARY HUMANMAST CELL CULTURES
CD34+ progenitor cells were positively selected from umbilical
cord or adult peripheral blood by double passage through columns
(Miltenyi Biotech) leading to cellular preparations containing
more than 98% CD34+ cells and negative for CD3, CD10, CD14,
CD19, CD20, CD40, CD56, CD83, CDw125 (IL-5R), and FcεR1.
All samples were collected after informed consent, using proto-
cols approved by the ethic committee at our institution. To obtain
MCs, CD34+ progenitor cells were cultured in StemPro serum
free culture medium (Invitrogen) supplemented with 5 ng/ml of
IL-3 and 100 ng/ml of SCF as described elsewhere (10). After 10–
12 weeks of culture, >98% of cells were stained for c-kit (BD),
FcεRI (e-BioScience), and tryptase (Chemicon). MCs were cul-
tured for 96 h with IgE (1µg/ml; generous gift of Dr. K. Ishizaka),
then extensively washed and crosslinked with anti-IgE (0.5µg/ml;
RayBiotech Inc.) overnight; their supernatants were collected or
in some experiments MCs were used in the upper compartment
of Transwell system.
Antibodies and recombinant cytokines used included: anti-
CD34-APC, anti-CD34-PE, anti-CD117-PE, anti-CD123-PE,
anti-CD3-PE, anti-CD14-PE, anti-CD19-FITC, anti-CD20-PE,
anti-CD56-PE (all from BD), anti-FcεRI (e-BioScience), anti-IL-
5R (generous gift of Dr. Tavernier), polyclonal anti-TSLP (Pro-
Science Inc.), recombinant TNF-α, IL-1β (R&D; 25 and 10 ng/ml,
respectively, or 1 ng/ml each when indicated); IL-3, IL-5 (Pepro-
Tech; each used at 5 ng/ml). Neutralizing antibody to TSLP
(Amgen) and its isotype control antibody were used at 10µg/ml,
as in our previous study (4).
PRIMARY HUMAN BONE MARROW-DERIVED MESENCHYMAL
STROMAL CELLS
Human BM-derived mesenchymal stromal cells were established
from BM samples (AllCells, Emeryville, CA, USA) by culture
in minimum essential medium-α, supplemented with 10% FBS
(Hyclone) and 5 ng/ml of basic fibroblast growth factor (FGF;
PeproTech). The cells were plated in 24-well plates until conflu-
ent, they were then washed with PBS three times to remove the
serum components and were co-cultured with CD34+ progenitor
cells or MCs, as indicated. In the experiment to separate MCs and
the stromal cell monolayer, Transwell with a 0.45µm filter in 24-
well plates were used. The supernatants from the various culture
conditions were collected and filtered to remove cellular debris.
Flow cytometric analysis confirmed that the BM-MSCs expressed
CD9, CD10, CD13, CD29, CD44, CD73, CD90, CD105, CD106,
and CD166, but not CD14, CD34, or CD45 (all from BioLegend).
PROLIFERATION ASSAY
CD34+ cells were labeled with CFSE and placed in the lower com-
partment of the Transwell system with or without BM-MSCs; in
some experiments, IgE-coated MCs (105 cells/ml) were cultured
in the upper compartment of the Transwell system in the presence
or absence of anti-IgE. MCs were removed after 6 h of culture. At
day 3 of cultures, CD34+ cells were gently removed from the BM-
MSCs layers (adherent cells) and analyzed for their proliferation
by FACS.
ASSESSMENT OF CYTOKINE RELEASE
Cell-free culture supernatants were analyzed for protein content
using commercially available kits, including IL-5, IL-13, G-CSF,
GM-CSF, SDF-1, and TSLP (all obtained from R&D).
QUANTITATIVE REAL-TIME PCR
RNA was isolated using the RNeasy Mini Kit (QIAGEN). cDNA
synthesis was performed using the TaqMan Reverse Transcription
kit. The CEBPA gene expression assay ID (from Applied Biosys-
tems, ABI) is Hs00269972_s1. The GATA-2 gene expression assay
ID is Hs00231119_m1. Quantitative real-time PCR was performed
via TaqMan using ABI gene expression assays on a 7900HT Fast
Real-Time PCR System. HPRT was used as a control for cDNA
input.
IMMUNOCYTOCHEMISTRY
Bone marrow-MSCs were cultured on eight-chamber slides until
they reached the confluence. The cells were stimulated with
or without IL-1/TNF or supernatants of activated MCs (30%
v/v), then fixed and stained for TSLP (polyclonal Ab, ProSci
Inc.), developed with AEC (Dako) and counterstained with
hematoxylin.
STATISTICAL ANALYSIS
Student’s paired and unpaired t tests were used when appropriate;
*p< 0.05, **p< 0.01, ***p< 0.001.
RESULTS
BONE MARROW STROMAL CELLS PRODUCE TSLP
Since TSLP is a growth factor released by thymic stromal cells
that exerts its effect on proliferation of immature lymphocytes,
we have focused on the role of TSLP in the cross-talk of BM-
derived mesenchymal stromal cells and CD34+ progenitor cells
which is likely to take place within the BM stroma. Unexpect-
edly, we observed that TSLP is expressed both at protein and
mRNA levels by BM-MSCs at low levels under steady state condi-
tions and is markedly enhanced in the presence of the canonical
proinflammatory cytokines IL-1 and TNF, which mimic inflam-
matory condition (Figure 1A). BM-MSCs-derived TSLP is biolog-
ically active and specific, as it induced IL-5 and IL-13 production
by freshly isolated CD34+ progenitor cells following overnight
cultures with BM-MSCs in the presence of suboptimal concen-
trations of IL-1/TNF [just sufficient to exert permissive effect
on TSLP, as previously published (9)] and it was suppressed by
Frontiers in Immunology | Inflammation December 2013 | Volume 4 | Article 461 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Allakhverdi et al. Activation of stromal cells by mast cells
neutralizing mAb to TSLP (Figure 1B). These observations thus
suggest that TSLP may be produced under both inflammatory and
steady state conditions and could serve as molecular regulator of
hematopoiesis and inflammation perhaps via induction of Th2
cytokines by CD34+ progenitor cells.
In view of MCs as the first cells to be activated upon exposure
to allergen, we next examined whether activated MCs would exert
similar effects as IL-1/TNF on the BM. Indeed, the soluble factors
released by IgE/anti-IgE-activated MCs induce TSLP production
by BM-MSCs as detected by ELISA (Figure 2A). Moreover, the lev-
els of TSLP present in these culture supernatants were sufficient
when used together with IL-1/TNF to induce IL-13 production
from CD34+ cells (Figure 2B). These observations were confirmed
by immunocytochemistry showing more intense staining of TSLP
FIGURE 1 | Bone marrow-derived mesenchymal stromal cells produce
TSLP upon stimulation with the proinflammatory cytokines IL-1 andTNF.
(A) The expression of TSLP was determined at the mRNA and protein level on
the bone marrow-derived mesenchymal stromal cells (BM-MSCs) stimulated
with or without IL-1/TNF (10 and 25 ng/ml, respectively); mean±SEM of five
experiments. (B) Freshly isolated neonatal CD34+ cells were co-cultured
overnight with BM-MSCs in the presence or absence of suboptimal
concentrations of IL-1/TNF (1 ng/ml of each) and neutralizing antibody to TSLP,
as indicated. Isotype control antibody had no biological activity. Supernatants
were assessed for IL-5 and IL-13 levels. Mean±SEM of eight experiments.
FIGURE 2 | Activated mast cells induceTSLP production by
BM-derived mesenchymal stromal cells. (A) Supernatants of activated
(IgE/anti-IgE) mast cells (30% v/v) were added to the BM-MSCs. TSLP
expression was analyzed by ELISA. Mean±SEM of four experiments.
(B) Freshly isolated neonatal CD34+ cells were cultured overnight with
BM-MSCs in the presence or absence of IgE/anti-IgE-activated MCs
supernatants, suboptimal concentrations of IL-1/TNF (1 ng/ml of each), and
neutralizing antibody to TSLP (10µg/ml), as indicated and supernatants
were assessed for IL-13 release. Control isotype antibody had no activity.
Mean±SEM of eight experiments. (C) Representative staining of
mesenchymal stromal cells cultured under conditions indicated with
anti-TSLP polyclonal antibody.
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protein on BM-MSCs stimulated with IL-1/TNF or supernatants
of activated MCs (Figure 2C). Treatment of BM-MSCs with MCs
mediators, including LTC4, PGD2, tryptase, and histamine alone or
in combination did not induce TSLP production, which required
the combination of all these mediators in the presence of TNF
(Table 1).
ACTIVATED MAST CELLS INDUCE GROWTH FACTOR PRODUCTION BY
BONE MARROWMESENCHYMAL STROMAL CELLS
Since shortly after allergen exposure there is increased prolifer-
ation and mobilization of CD34+ progenitors from the BM as
well as an augmented differentiation of eosinophils, we examined
whether activated MCs stimulate BM-MSCs for the increased pro-
duction of hematopoietic growth factors. In the experiment shown
in Figure 3, BM-MSCs were cultured for 6 h with activated MCs
in a Transwell system then MCs were removed and BM-MSCs
were kept in culture for another 42 h. In addition to TSLP, BM-
MSCs released G-CSF and GM-CSF, factors with critical roles in
hematopoiesis. Moreover, the production of SDF-1 was signifi-
cantly reduced in the presence of activated MCs. Attenuation of
SDF-1 receptor expression on the BM CD34+ cells together with
Table 1 | Mast cell mediators’ effect on the release ofTSLP by
BM-MSCs.
Conditions TSLP (pg/ml)
BM-MSCs (−) 18±2.1
TNF 35±5.5
LTC4 N/D
Tryptase N/D
Histamine N/D
PGD2 N/D
LTC4/tryptase/histamine N/D
LTC4/tryptase/histamine+TNF 252±7.8
N/D, not detected; the results are presented as mean±SEM.
reduction of SDF-1 levels in the BM was shown to regulate the
release of progenitors from BM in allergen induced asthma (2,
11). Of note, the supernatants of cultures that were harvested at
the point when MCs were removed contained no detectable levels
of TSLP, G-CSF, and GM-CSF.
BONE MARROWMESENCHYMAL STROMAL CELLS PRIMED WITH
ACTIVATED MAST CELLS INDUCE PROLIFERATION OF CD34+
PROGENITORS
Because allergen exposure increases proliferation of CD34+ prog-
enitors in the BM (12) and at the site of allergen exposure (13),
we next analyzed whether activated MCs would have an effect
on the proliferation of the progenitors. Indeed, MCs-derived sol-
uble factors enhanced the proliferation of CFSE-labeled CD34+
progenitor cells as determined at day 3 of cultures. Non-activated
MCs exerted a small but consistent effect on the proliferation of
CD34+ cells likely due to background levels of activation. BM-
MSCs co-cultured with CD34+ cells in the lower compartment
of the Transwell system also enhanced progenitor proliferation.
The proliferation of CD34+ cells was markedly increased if BM-
MSCs were preactivated by soluble factors released by IgE/anti-
IgE-activated MCs in the upper compartment of Transwell, which
was removed after 6 h of culture (Figure 4).
BONE MARROWMESENCHYMAL STROMAL CELLS PRIMED WITH
ACTIVATED MAST CELLS REGULATE ALLERGY-RELATED EARLY GENES
IN CD34+ PROGENITORS
To assess whether MC-activated BM-MSCs might prime progen-
itor cell differentiation into allergic effectors, we have examined
the expression of early allergy-related genes in CD34+ progenitor
cells. After 10 h of co-culture with BM-MSCs pre-stimulated with
activated MCs, CD34+ progenitor cells demonstrated downreg-
ulated CEBP-α and upregulated GATA-2 expression, two genes
known to be implicated in the differentiation of progenitors
into allergic effectors (14) (Figure 5). Increased expression of
GATA-2 in CD34+ progenitors gives rise to eosinophil differenti-
ation, whereas a concomitant decrease in CEBP-α and increase in
FIGURE 3 | Activated mast cells induce hematopoietic growth factors
production by BM-derived mesenchymal stromal cells. BM-MSCs were
exposed to non-activated and activated MCs in a Transwell system for 6 h,
then Transwell membranes with mast cells were removed; the cultures of
stromal cells were left for additional 42 h and their supernatants were
analyzed for the production of cytokines (pg/ml). Supernatants of BM-MSCs
stimulated with IL-1/TNF (10 and 25 ng/ml, respectively) for 48 h were used as
a positive control. Mean±SEM of six to ten experiments.
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FIGURE 4 | Bone marrow-derived mesenchymal stromal cells
preactivated with mast cells induce proliferation of CD34+ progenitor
cells and regulate allergy-related genes in CD34+ progenitors.
CFSE-labeled freshly isolated CD34+ progenitor cells were co-cultured for
3 days with BM-MSCs exposed to activated in a Transwell system mast
cells (kept in cultures for 6 h while cross-linking with anti-IgE and then
removed) and their proliferation was assessed. Numbers refer to mean
fluorescence intensity (MFI) of CFSE-labeled CD34+-gated cells.
Representative of three experiments.
GATA-2 enforces basophil/MC differentiation (15). Collectively,
these data suggest that mesenchymal stromal cells stimulated with
activated MCs regulate proliferation and lineage commitment of
CD34+ progenitor cells.
DISCUSSION
The inflammatory process that occurs following allergen expo-
sure is characterized by the accumulation of immature precur-
sors, eosinophil-committed progenitors,mature eosinophils,MCs,
basophils, neutrophils, and CD4+ T cells, all of which are of BM
origin. The BM of allergic subjects releases increased amounts
of CD34+ progenitor cells that migrate to the sites of allergic
inflammation (2); these cells are readily detectable in the bronchial
mucosa and the sputum of asthmatic patients, in nasal polyps and
in the lesional skin of atopic dermatitis patients (13, 16). How-
ever, the mechanism behind the increased activation of the BM
following airway allergen exposure, resulting in both the release
of progenitors into the circulation and the production of new
effectors is not known. Here we suggest a possible mechanism by
which IgE-activated MCs trigger BM mesenchymal stromal cells
to release TSLP and hematopoietic growth factors and to regulate
the proliferation and lineage commitment of CD34+ precursor
cells.
In recent years, there has been an increasing appreciation of
important contribution of BM-related, hematopoietic mecha-
nisms to allergic diseases. Interesting observations indicated that
the BM is able to transfer all allergic manifestations (17, 18) while
lung transplantation transfers only asthma (19), thus suggesting
FIGURE 5 | Bone marrow-derived mesenchymal stromal cells
preactivated with mast cells regulate allergy-related genes in CD34+
progenitors. BM-MSCs were exposed to non-activated or activated mast
cells in a Transwell system and freshly isolated CD34+ cells were added to
the cultures for 10 h. Early genes for effector differentiation were analyzed
in CD34+ cells following culture with BM-MSCs by real-time PCR.
Mean±SEM of four experiments.
that resident BM cells play important role in the regulation of aller-
gic inflammation. Most of the hematopoietic activities in the BM
are controlled by the resident mesenchymal stromal cells and their
products (20). BM-MSCs have recently been shown to suppress
harmful immune responses in patients with steroid-resistant graft-
versus-host disease (21), severe systemic lupus erythematosus (22),
and cardiac disease (23). The authors of many of these studies con-
cluded that BM-MSCs-driven immunosuppression results from
a shift in Th1/Th2 balance (24, 25). Our results showing that
cytokines IL-1 and TNF, which mimic inflammatory conditions,
and also the products released by MCs following IgE-mediated
cross-linking induce production of Th2-inducing cytokine TSLP
by BM-MSCs may shed light on these observations. Functional
relevance of this observation is demonstrated by increased IL-5
and IL-13 production by CD34+ cells and expression of allergy-
associated genes by these progenitor cells after interaction with
MC-primed BM-MSCs. Importantly, accumulation of eosinophils
and basophils in tissues is characteristic of allergic inflammation
in rhinitis, nasal polyposis, and asthma (26, 27). These airway tis-
sue inflammatory events may be coincident with relevant changes
and fluctuations of circulating and marrow populations of CD34+
progenitors following mediators release by BM-MSCs. Indeed,
TSLP was suggested to play direct role in the IL-3-independent
differentiation of basophils (28). TSLP may also indirectly be
implicated in the observed increased eosinophilopoiesis in the
presence of IL-1-treated stromal cells (29) by inducing IL-5 release
by CD34+ progenitor cells. Furthermore, increased proliferation
and release of CD34+ cells in the presence of MCs-primed BM-
MSCs suggest a direct signal between the airway mucosa and
BM that is able to increase CD34+ production and release at
times of increased allergic inflammation. Accordingly, hematopoi-
etic growth factors released by BM-MSCs upon stimulation with
activated MCs could explain observed increased proliferation of
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FIGURE 6 | Schematic diagram showing systemic hematopoietic
processes involving active communication between mast cells at the
site of allergic inflammation and the bone marrow, highlighting how
mast cell-released mediators stimulate the bone marrow to produce
hematopoietic growth factors, which in turn regulate proliferation and
lineage commitment of CD34+ progenitor cells. CD34+ progenitor cells
stimulated with MC-primed BM-MSCs may produce IL-5 and IL-13 in the
bone marrow and at the sites of allergic inflammation via TSLP-dependent
mechanisms.
CD34+ cells in asthmatics 24 h after inhaled allergen challenge
(30). In addition to their effects on BM-MSCs, MCs products may
also act on epithelial cells inducing their release of TSLP (31)
and G-CSF (unpublished observations), which may also affect the
activity of BM. The finding that the production of SDF-1 by BM-
MSCs was significantly reduced in the presence of activated MCs
(Figure 3) suggests a possible mechanism for the increased mobi-
lization of CD34+ progenitor cells from the BM after allergen
challenge, because SDF-1 plays an important role in the homing
and retention of progenitor cells to the BM (11, 32). The obser-
vation that the MCs mediators could induce TSLP production
by BM-MSCs only in the presence of TNF could explain how
chronic inflammation increases the sensitization of the airways
to the allergen (33, 34). Notably, MCs can release TNF, especially
after IgE-mediated activation (35). In keeping with this, TNF was
reported to upregulate PAR-2 expression on endothelial cells (36).
Although it is tempting to speculate that serine proteases, including
tryptase, which is a natural ligand of PAR-2, could be implicated
in the induction of TSLP via PAR-2-dependent mechanism, as it
was reported for epithelial cells (37), the exact mechanism of TSLP
induction by BM-MSCs upon stimulation with activated MCs still
remains to be elucidated.
In conclusion, this study demonstrates that inflammation and
IgE-activated MCs stimulate BM-MSCs to release TSLP and other
growth factors, which in turn regulate proliferation and lineage
commitment of CD34+ progenitor cells and also their production
of Th2 cytokines. The in vivo relevance of these in vitro experi-
ments and the obvious question of how MCs-released mediators at
the site of allergen exposure reach the BM within minutes remain
to be determined. There is an emerging understanding of precisely
how this could happen via insoluble particles composed primarily
of heparin and cationic proteins, forming extracellular chaperons
and protecting these mediators from dilution into interstitial space
and degradation (38). Altogether, the present data further under-
line the important role of MCs in the pathophysiology of allergic
diseases by showing that these cells not only display proinflam-
matory activity at the site of allergen exposure but also induce
systemic response involving the BM (Figure 6), as it has been
suggested (39).
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